Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, Maccaro C, Bahgat A, Marzouk E, Cathcart E, Moskowitz A, Noy A, Kumar A, Jacobsen E, Fisher DC, Mehta-Shah N, Kim YH, Khodadoust M, Kotlov N, Nikitina A, Kudryashova O, Zubareva V, Zornikova K, Shin N, Sorokina M, Degryse S, Postovalova E, Bagaev A, Hosszu K, McAvoy D, Boelens JJ, Wu W, Ciantra Z, Appelt JW, Trevisani C, Amaka S, Weinstock DM, Vardhana SA.

Open source

DOI: 10.1038/s41591-024-03076-6
Published: 2024-06-17
Container: Nat Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-024-03076-6,
  title = {Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.},
  author = {Horwitz SM and  Nirmal AJ and  Rahman J and  Xu R and  Drill E and  Galasso N and  Ganesan N and  Davey T and  Hancock H and  Perez L and  Maccaro C and  Bahgat A and  Marzouk E and  Cathcart E and  Moskowitz A and  Noy A and  Kumar A and  Jacobsen E and  Fisher DC and  Mehta-Shah N and  Kim YH and  Khodadoust M and  Kotlov N and  Nikitina A and  Kudryashova O and  Zubareva V and  Zornikova K and  Shin N and  Sorokina M and  Degryse S and  Postovalova E and  Bagaev A and  Hosszu K and  McAvoy D and  Boelens JJ and  Wu W and  Ciantra Z and  Appelt JW and  Trevisani C and  Amaka S and  Weinstock DM and  Vardhana SA.},
  year = {2024},
  journal = {Nat Med},
  doi = {10.1038/s41591-024-03076-6},
  url = {https://doi.org/10.1038/s41591-024-03076-6}
}

RIS

TY  - JOUR
TI  - Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
AU  - Horwitz SM
AU  -  Nirmal AJ
AU  -  Rahman J
AU  -  Xu R
AU  -  Drill E
AU  -  Galasso N
AU  -  Ganesan N
AU  -  Davey T
AU  -  Hancock H
AU  -  Perez L
AU  -  Maccaro C
AU  -  Bahgat A
AU  -  Marzouk E
AU  -  Cathcart E
AU  -  Moskowitz A
AU  -  Noy A
AU  -  Kumar A
AU  -  Jacobsen E
AU  -  Fisher DC
AU  -  Mehta-Shah N
AU  -  Kim YH
AU  -  Khodadoust M
AU  -  Kotlov N
AU  -  Nikitina A
AU  -  Kudryashova O
AU  -  Zubareva V
AU  -  Zornikova K
AU  -  Shin N
AU  -  Sorokina M
AU  -  Degryse S
AU  -  Postovalova E
AU  -  Bagaev A
AU  -  Hosszu K
AU  -  McAvoy D
AU  -  Boelens JJ
AU  -  Wu W
AU  -  Ciantra Z
AU  -  Appelt JW
AU  -  Trevisani C
AU  -  Amaka S
AU  -  Weinstock DM
AU  -  Vardhana SA.
PY  - 2024
JO  - Nat Med
DO  - 10.1038/s41591-024-03076-6
UR  - https://doi.org/10.1038/s41591-024-03076-6
ER  -

APA

SM, H., AJ, N., J, R., R, X., E, D., N, G., N, G., T, D., H, H., L, P., C, M., A, B., E, M., E, C., A, M., A, N., A, K., E, J., DC, F., N, M., YH, K., M, K., N, K., A, N., O, K., V, Z., K, Z., N, S., M, S., S, D., E, P., A, B., K, H., D, M., JJ, B., W, W., Z, C., JW, A., C, T., S, A., DM, W., & SA., V. (2024). Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.. Nat Med. https://doi.org/10.1038/s41591-024-03076-6

Source records

europe-pmc · retrieved 2026-09-27T12:22:29.625Z